[Risedronate].
Risedronate (RSD) containing nitrogen, the third generation of bisphosphonate, has a powerful antiresorptive activity, without a stronger inhibition of mineralization. RSD is available for the treatment of osteoporosis. In Japanese the effective dose is 2.5 mg given orally daily, while in Caucasians it is 5 mg. This difference of dose suggests that RSD may be absorbed more efficiently in Japanese than in Caucasians. RSD administered orally at 2.5 mg per day for 48 weeks induced a 5% increase of bone mineral density in the lumbar spines in osteoporotic women. RSD, 5 mg daily, decreases vertebral and non-vertebral, especially hip fractures in elderly osteoporotic women. Thus, RSD is an important agent for the treatment of osteoporosis.
Fukunaga
Masao
M
Department of Nuclear Medicine, Kawasaki Medical School.
D000368:Aged; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D000068296:Risedronic Acid
D000068296:Risedronic Acid; D012968:Etidronic Acid